Bayer (BAYN) Given a €123.00 Price Target at Baader Bank

Bayer (FRA:BAYN) received a €123.00 ($143.02) target price from equities researchers at Baader Bank in a report issued on Tuesday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the healthcare company’s stock. Baader Bank’s target price would suggest a potential upside of 117.89% from the stock’s previous close.

A number of other brokerages also recently commented on BAYN. Deutsche Bank set a €115.00 ($133.72) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Friday, March 1st. Barclays set a €85.00 ($98.84) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Monday, March 4th. JPMorgan Chase & Co. set a €70.00 ($81.40) target price on shares of Bayer and gave the stock a “neutral” rating in a research note on Friday, March 1st. Kepler Capital Markets set a €84.00 ($97.67) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Wednesday, February 27th. Finally, Nord/LB set a €72.00 ($83.72) target price on shares of Bayer and gave the stock a “neutral” rating in a research note on Wednesday, February 27th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of €81.67 ($94.97).

Shares of BAYN stock opened at €56.45 ($65.64) on Tuesday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: Golden Cross

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.